Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss

Michelle M. Mielke, Norman J. Haughey, Veera Venkata Ratnam Bandaru, Steven Schech, Richard Carrick, Michelle C. Carlson, Susumu Mori, Michael I. Miller, Can Ceritoglu, Timothy Brown, Marilyn Albert, Constantine G. Lyketsos

Research output: Contribution to journalArticle

82 Scopus citations

Abstract

Background: A blood-based biomarker of Alzheimer's disease (AD) would be superior to cerebrospinal fluid (CSF) and neuroimaging measures in terms of cost, invasiveness, and feasibility for repeated measures. We previously reported that blood ceramides varied in relation to timing of memory impairment in a population-based study. The present objective was to examine whether plasma ceramides varied by AD severity in a well-characterized clinic sample and were associated with cognitive decline and hippocampal volume loss over 1 year. Methods: Participants included 25 normal controls (NC), 17 amnestic Mild Cognitive Impairment (MCI), and 21 early probable AD. A thorough neuropsychological battery and neuroimaging with hippocampal volume determination were conducted at baseline and 1 year later. Plasma ceramides were assayed at baseline using high performance liquid chromatography coupled electrospray ionization tandem mass spectrometry. Results: Although all saturated ceramides were lower in MCI compared with AD at baseline, ceramides C22:0 and C24:0 were significantly lower in the MCI group compared with both NC and AD groups (P < .01). Ceramide levels did not differ (P > .05) in AD versus NC. There were no cross-sectional associations between ceramides C22:0 and C24:0 and either cognitive performance or hippocampal volume among any group. However, among the MCI group, higher baseline ceramide C22:0 and C24:0 levels were predictive of cognitive decline and hippocampal volume loss 1 year later. Conclusion: Results suggest that very long-chain plasma ceramides C22:0 and C24:0 are altered in MCI and predict memory loss and right hippocampal volume loss among subjects with MCI. These plasma ceramides may be early indicators of AD progression.

Original languageEnglish (US)
Pages (from-to)378-385
Number of pages8
JournalAlzheimer's and Dementia
Volume6
Issue number5
DOIs
StatePublished - Sep 1 2010

Keywords

  • Biomarker
  • Ceramides
  • Hippocampal volume
  • Lipids
  • Mild cognitive impairment
  • Plasma

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss'. Together they form a unique fingerprint.

  • Cite this

    Mielke, M. M., Haughey, N. J., Ratnam Bandaru, V. V., Schech, S., Carrick, R., Carlson, M. C., Mori, S., Miller, M. I., Ceritoglu, C., Brown, T., Albert, M., & Lyketsos, C. G. (2010). Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimer's and Dementia, 6(5), 378-385. https://doi.org/10.1016/j.jalz.2010.03.014